Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 16 · above the Ichimoku cloud · RSI 42 · MACD below its signal
| 1.56 | 52-week high | +60.00% |
| 1.50 | Previous month high | +53.85% |
| 1.22 | R3 (classic) | +24.64% |
| 1.18 | Previous week high | +21.54% |
| 1.16 | R2 (classic) | +19.41% |
| 1.11 | Previous day high | +14.18% |
| 1.07 | R1 (classic) | +9.71% |
| 1.02 | Pivot | +4.48% |
| 0.9750 | Price now | |
| 0.9677 | Previous day low | −0.75% |
| 0.9677 | Previous week low | −0.75% |
| 0.9240 | S1 (classic) | −5.23% |
| 0.8731 | S2 (classic) | −10.45% |
| 0.7784 | S3 (classic) | −20.16% |
| 0.7210 | Previous month low | −26.05% |
| 0.5010 | 52-week low | −48.62% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $43.6K | 0.00% | 58.10K | +10% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TELA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Capper Joseph HDirector | Purchase at price 1.02 - 1.06 per share. | 75K | $78.44K |
| Aug 16, 2026 | Getz Heather CChief Executive Officer | Purchase at price 0.66 per share. | 12.5K | $8.31K |
| Aug 13, 2026 | Getz Heather CChief Executive Officer | Purchase at price 0.70 per share. | 15K | $10.47K |
| Aug 2, 2026 | Getz Heather CChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 500K | — |
| Jul 14, 2026 | Capper Joseph HDirector | Stock Award(Grant) at price 0.78 per share. | 6.2K | $4.89K |
| Jul 14, 2026 | Plovanic William J.Director | Stock Award(Grant) at price 0.78 per share. | 20.9K | $16.43K |
| Jun 8, 2026 | Nohra Guy PDirector | Stock Award(Grant) at price 0.00 per share. | 23.6K | — |
| Jun 8, 2026 | Thomas Paul GDirector | Stock Award(Grant) at price 0.00 per share. | 23.6K | — |
| Jun 8, 2026 | Neels Guido JDirector | Stock Award(Grant) at price 0.00 per share. | 23.6K | — |
| Jun 8, 2026 | Capper Joseph HDirector | Stock Award(Grant) at price 0.00 per share. | 23.6K | — |
| Jun 8, 2026 | Plovanic William J.Director | Stock Award(Grant) at price 0.00 per share. | 11.7K | — |
| Jun 8, 2026 | Rocchio Betty JoDirector | Stock Award(Grant) at price 0.00 per share. | 11.7K | — |
| Feb 19, 2026 | Koblish AntonyChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 176K | — |
| Feb 19, 2026 | Cuca RobertoChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 57K | — |
| Feb 19, 2026 | Talmo PaulChief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 57K | — |
| Feb 19, 2026 | Firestone Gregory AOfficer | Stock Award(Grant) at price 0.00 per share. | 37K | — |
| Feb 19, 2026 | Blizard JeffreyPresident | Stock Award(Grant) at price 0.00 per share. | 86K | — |
| Feb 17, 2026 | Smeykal MeganOfficer | Stock Award(Grant) at price 0.00 per share. | 32.9K | — |
| Nov 16, 2025 | Ew Healthcare Partners Fund 2, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 1.11 per share. | 3.60M | $4.00M |
| Oct 30, 2025 | Plovanic William J.Director | Stock Award(Grant) at price 0.00 per share. | 11.9K | — |
TimeframesUp on the weekly, down on the hourly and monthly, mixed on the daily.
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
over a rising 21 EMA, 21 over 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.3 | -13.2 | -28.6 | 41.1 | 10.9 | -22.7 | -2.7 | 1.1 | 55.8 | -15.2 | −17.4% | ||
| 2025 | -12.6 | -7.2 | -50.2 | -20.5 | 43.3 | 39.6 | -12.4 | 4.7 | -16.3 | -17.4 | -6.5 | 2.6 | −60.9% |
| 2024 | 4.4 | -2.2 | -16.1 | -20.5 | 22.8 | -15.0 | -5.3 | -34.8 | -12.8 | 11.1 | 11.7 | -3.8 | −54.4% |
| 2023 | 0.7 | -8.8 | 0.8 | -11.7 | 7.8 | 0.0 | -3.4 | -1.3 | -17.2 | -27.0 | -10.8 | 27.1 | −42.4% |
| 2022 | -4.6 | 4.9 | -9.2 | -20.4 | -24.5 | 0.3 | 15.1 | 4.3 | 1.2 | 4.7 | -5.9 | 37.1 | −10.2% |
| 2021 | -4.9 | 7.5 | -3.1 | -8.2 | 0.4 | 17.2 | -6.6 | -13.0 | 4.3 | -5.8 | -3.7 | 3.2 | −14.9% |
| 2020 | 15.1 | 4.0 | -49.5 | 46.7 | 19.9 | -5.7 | -10.2 | 22.4 | 16.1 | -8.3 | 8.0 | -8.1 | +16.1% |
| 2019 | -6.2 | −6.2% |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Buy / hold / sell counts